Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in pregnant women at high risk for early-onset severe HDFN
NL-OMON52622Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nipocalimab in Erythroblastosis fetalis (HDFN), sponsored by Janssen Pharmaceutical. Primary endpoints: Maternal safety and tolerability, Neonatal and infant safety and 1 more. Started Jun 2019; status: completed.
02
Drugs
nipocalimab
03
Conditions
Erythroblastosis fetalis (HDFN)
Beyond the preview
Go deeper on NL-OMON52622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52622.